# Hiddo J.L. Heerspink

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hiddo-j-l-heerspink/

## Facts

| Field | Value |
| --- | --- |
| Citations | 66,421 |
| Field | Diabetes Treatment and Management |
| h-index | 121 |
| i10-index | 510 |
| Last Known Institution | New South Wales Department of Health |
| OpenAlex ID | https://openalex.org/A5031624913 |
| ORCID iD | 0000-0002-3126-3730 |
| Works | 1,082 |

## Researcher papers

Showing 12 of 69.

- [Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/canagliflozin-and-renal-outcomes-in-type-2-diabetes-and-nephropathy/)
- [Dapagliflozin in Patients with Chronic Kidney Disease](https://scholariq.org/papers/dapagliflozin-in-patients-with-chronic-kidney-disease/)
- [Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention](https://scholariq.org/papers/chronic-kidney-disease-and-cardiovascular-risk-epidemiology-mechanisms-and/)
- [Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis](https://scholariq.org/papers/associations-of-kidney-disease-measures-with-mortality-and-end-stage-renal/)
- [Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus](https://scholariq.org/papers/sodium-glucose-cotransporter-2-inhibitors-in-the-treatment-of-diabetes-mellitus/)
- [KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease](https://scholariq.org/papers/kdigo-2022-clinical-practice-guideline-for-diabetes-management-in-chronic-kidney/)
- [Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease](https://scholariq.org/papers/bardoxolone-methyl-in-type-2-diabetes-and-stage-4-chronic-kidney-disease/)
- [Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials](https://scholariq.org/papers/impact-of-diabetes-on-the-effects-of-sodium-glucose-co-transporter-2-inhibitors/)
- [Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy](https://scholariq.org/papers/global-kidney-health-2017-and-beyond-a-roadmap-for-closing-gaps-in-care-research/)
- [Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment](https://scholariq.org/papers/glomerular-hyperfiltration-in-diabetes-mechanisms-clinical-significance-and/)
- [SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis](https://scholariq.org/papers/sglt2-inhibitors-for-the-prevention-of-kidney-failure-in-patients-with-type-2/)
- [Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure](https://scholariq.org/papers/multinational-assessment-of-accuracy-of-equations-for-predicting-risk-of-kidney/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)

## Researcher university

- [New South Wales Department of Health](https://scholariq.org/institutions/new-south-wales-department-of-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.